Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 19.69

Shanghai Yizhong Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) is 19.69 on January 14, 2025, a -25.50% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Shanghai Yizhong Pharmaceutical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 29.17 on November 13, 2024, which is 48.19% above the current Price to Sales Ratio (P/S).
Shanghai Yizhong Pharmaceutical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 8.80 on July 24, 2024, which is -55.28% below the current Price to Sales Ratio (P/S).
Shanghai Yizhong Pharmaceutical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 17.60.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd.

CEO	Mr. Jingsong Zhou
IPO Date	Sept. 9, 2021
Location	China
Headquarters	No.79 Renqi Road
Employees	304
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.

Key trends

Past 5 years